Creating a 3D liver model to test treatments for non-alcoholic fatty liver disease
Re-engineering a human 3D liver tissue model for non-alcoholic fatty liver disease for drug screening
This study is creating a 3D model of human liver tissue to better understand non-alcoholic fatty liver disease (NAFLD) and test over 100 different drugs to find new treatments that could help people with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11094031 on NIH RePORTER |
What this research studies
This research focuses on developing a human 3D liver tissue model specifically designed to study non-alcoholic fatty liver disease (NAFLD). By using patient-derived liver cells, the team aims to create a more accurate representation of the disease, allowing for better drug screening and testing. The project involves testing over 100 drugs and combinations to identify potential treatments, utilizing advanced techniques like quantitative systems pharmacology. This innovative approach aims to enhance the understanding of NAFLD and improve the precision of future therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with non-alcoholic fatty liver disease.
Not a fit: Patients with liver diseases unrelated to non-alcoholic fatty liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments for non-alcoholic fatty liver disease, benefiting millions of patients worldwide.
How similar studies have performed: Previous research has shown promise in using 3D tissue models for drug testing, indicating a potential for success with this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Miedel, Mark T. — University of Pittsburgh at Pittsburgh
- Study coordinator: Miedel, Mark T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.